4.8 Article

Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses

Journal

IMMUNITY
Volume 53, Issue 6, Pages 1230-+

Publisher

CELL PRESS
DOI: 10.1016/j.immuni.2020.10.005

Keywords

-

Categories

Funding

  1. National Institute of Allergy and Infectious Diseases (NIAID)
  2. National Institutes of Health [U19AI082724, U19AI109946, U19AI057266, P01 AI097092, R01AI145870-01, T32AI007244-36]
  3. NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400005C, HHSN272201400008C]
  4. NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
  5. Austrian Science Fund [P30565]
  6. Bill and Melinda Gates Foundation [OPP1084518]
  7. Bill & Melinda Gates Foundation
  8. Bill and Melinda Gates Foundation [OPP1084518] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

Polyreactivity is the ability of a single antibody to bind to multiple molecularly distinct antigens and is a common feature of antibodies induced upon pathogen exposure. However, little is known about the role of polyreactivity during anti-influenza virus antibody responses. By analyzing more than 500 monoclonal antibodies (mAbs) derived from B cells induced by numerous influenza virus vaccines and infections, we found mAbs targeting conserved neutralizing influenza virus hemagglutinin epitopes were polyreactive. Polyreactive mAbs were preferentially induced by novel viral exposures due to their broad viral binding breadth. Polyreactivity augmented mAb viral binding strength by increasing antibody flexibility, allowing for adaption to imperfectly conserved epitopes. Lastly, we found affinity-matured polyreactive B cells were typically derived from germline polyreactive B cells that were preferentially selected to participate in B cell responses over time. Together, our data reveal that polyreactivity is a beneficial feature of antibodies targeting conserved epitopes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available